| Symbol | VTGN |
|---|---|
| Name | VISTAGEN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 343 ALLERTON AVE., SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 - 577-3600 |
| Fax | — |
| — | |
| Website | https://www.vistagen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001411685 |
| Description | Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagens pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Vistagen Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000947871-26-000804 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G/A - Vistagen Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352371 <b>Size:</b> 22 KB
Read moreNew Form SCHEDULE 13G/A - Vistagen Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001831942-26-000032 <b>Size:</b> 15 KB
Read more(30% Negative) VISTAGEN THERAPEUTICS, INC. (VTGN) Reports Q3 2026 Financial Results
Read moreVistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Read moreVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Read moreNew Form DEF 14A - Vistagen Therapeutics, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0001628280-26-051404 <b>Size:</b> 5 MB
Read moreWilliamson Douglas J 🟢 acquired 40.8K shares (1 derivative) of Vistagen Therapeutics, Inc. (VTGN) at $0.24 Transaction Date: Jul 29, 2026 | Filing ID: 000006
Read more(70% Positive) VISTAGEN THERAPEUTICS, INC. (VTGN) Provides Update on experience for neuroscience drug development
Read moreNew Form 3 - Vistagen Therapeutics, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0001911501-26-000004 <b>Size:</b> 15 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06809179 | A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat D… | Phase2 | Social Anxiety Disorder | Recruiting | 2025-01-09 | 2026-12-01 | ClinicalTrials.gov |
| NCT06615557 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social… | Phase3 | Social Anxiety Disorder (SAD) | Active_Not_Recruiting | 2024-09-16 | 2027-04-01 | ClinicalTrials.gov |
| NCT06358651 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social… | Phase3 | Social Anxiety Disorder | Active_Not_Recruiting | 2024-03-28 | 2026-10-01 | ClinicalTrials.gov |
| NCT04147949 | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Ind… | Phase2 | Parkinson Disease | Unknown | 2022-08-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT05280054 | AV-101 Alone and in Combination With Probenecid in Healthy Subjects | Phase1 | Drug Drug Interaction | Unknown | 2021-12-23 | 2022-11-01 | ClinicalTrials.gov |
| NCT04404192 | PH94B in the Treatment of Adjustment Disorder With Anxiety | Phase2 | Adjustment Disorder With Anxious Mood | Completed | 2021-10-12 | 2022-12-14 | ClinicalTrials.gov |
| NCT05030350 | Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD) | Phase3 | Social Anxiety Disorder | Terminated | 2021-10-01 | 2022-09-23 | ClinicalTrials.gov |
| NCT05011396 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 | Phase3 | Social Anxiety Disorder | Terminated | 2021-08-30 | 2022-08-16 | ClinicalTrials.gov |
| NCT04754802 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge | Phase3 | Social Anxiety Disorder | Completed | 2021-05-24 | 2022-06-22 | ClinicalTrials.gov |
| NCT03583554 | Electrophysiological Biomarkers of AV-101 | Phase1 | Healthy | Completed | 2018-09-01 | 2019-10-19 | ClinicalTrials.gov |
| NCT03078322 | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression | Phase2 | Major Depressive Disorder | Completed | 2018-03-05 | 2019-10-01 | ClinicalTrials.gov |
| NCT01483846 | Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Health… | Phase1 | Neuropathic Pain | Completed | 2011-12-01 | 2012-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | ACTIVE_NOT_RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder | COMPLETED | NCT04754802 |
| PH94B Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder | COMPLETED | NCT04754802 |
| Placebo | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT01483846 |
| AV-101 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT01483846 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03078322 |
| AV-101 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT03078322 |
| Placebo | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT04147949 |
| AV-101 | Other | Phase PHASE2 | Parkinson Disease | UNKNOWN | NCT04147949 |
| AV-101 1440 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03583554 |
| AV-101 720 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03583554 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03583554 |
| Probenecid | Other | Phase PHASE1 | Drug Drug Interaction | UNKNOWN | NCT05280054 |
| AV-101 | Other | Phase PHASE1 | Drug Drug Interaction | UNKNOWN | NCT05280054 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder | ACTIVE_NOT_RECRUITING | NCT06358651 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder | ACTIVE_NOT_RECRUITING | NCT06358651 |
| Placebo | Other | Phase PHASE2 | Adjustment Disorder With Anxious Mood | COMPLETED | NCT04404192 |
| PH94B | Other | Phase PHASE2 | Adjustment Disorder With Anxious Mood | COMPLETED | NCT04404192 |
| PH94B | Other | Phase PHASE3 | Social Anxiety Disorder | TERMINATED | NCT05030350 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder | TERMINATED | NCT05011396 |
| PH94B Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder | TERMINATED | NCT05011396 |
| Placebo Nasal Spray - Placebo Nasal Spray | Other | Phase PHASE2 | Social Anxiety Disorder | RECRUITING | NCT06809179 |
| Fasedienol Nasal Spray - Fasedienol Nasal Spray | Other | Phase PHASE2 | Social Anxiety Disorder | RECRUITING | NCT06809179 |
| Fasedienol Nasal Spray - Placebo Nasal Spray | Other | Phase PHASE2 | Social Anxiety Disorder | RECRUITING | NCT06809179 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Fasedienol Nasal Spray | Other | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Placebo Nasal Spray - Placebo Nasal Spray | DRUG | Phase PHASE2 | Social Anxiety Disorder | RECRUITING | NCT06809179 |
| Fasedienol Nasal Spray - Fasedienol Nasal Spray | DRUG | Phase PHASE2 | Social Anxiety Disorder | RECRUITING | NCT06809179 |
| Fasedienol Nasal Spray - Placebo Nasal Spray | DRUG | Phase PHASE2 | Social Anxiety Disorder | RECRUITING | NCT06809179 |
| Fasedienol Nasal Spray | DRUG | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| Probenecid | DRUG | Phase PHASE1 | Drug Drug Interaction | UNKNOWN | NCT05280054 |
| Placebo Nasal Spray | DRUG | Phase PHASE3 | Social Anxiety Disorder (SAD) | RECRUITING | NCT06615557 |
| PH94B Nasal Spray | DRUG | Phase PHASE3 | Social Anxiety Disorder | TERMINATED | NCT05011396 |
| PH94B | DRUG | Phase PHASE3 | Social Anxiety Disorder | TERMINATED | NCT05030350 |
| AV-101 1440 mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03583554 |
| AV-101 720 mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03583554 |
| Placebo | DRUG | Phase PHASE2 | Adjustment Disorder With Anxious Mood | COMPLETED | NCT04404192 |
| AV-101 | DRUG | Phase PHASE1 | Drug Drug Interaction | UNKNOWN | NCT05280054 |